Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell 2Oligodendroglioma 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Inflammatory Breast Neoplasms 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 3Paclitaxel 3Docetaxel 3Taxes 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tipifarnib 1romidepsin 1pertuzumab 1pegfilgrastim 1onvansertib 1neratinib 1grapiprant 1eribulin 1caficrestat 1Peripheral Blood Stem Cell Transplantation 1PF-05280014 1Ontruzant 1Ogivri 1Mesna 1Lapatinib 1Filgrastim 1Epirubicin 1Doxorubicin 1Depsipeptides 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inflammatory Breast Neoplasms × Depsipeptides × Clear all
NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Thomas Jefferson University

Phase 1/2 Terminated
9 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡